An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Virology Journal Year : 2010

An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.

Shihui Sun
  • Function : Author
  • PersonId : 919924
Lanying Du
  • Function : Author
  • PersonId : 919925
Zhitao Ru
  • Function : Author
  • PersonId : 919927
Zhihua Kou
  • Function : Author
  • PersonId : 919928
Yan Guo
  • Function : Author
  • PersonId : 919929
Hong Yu
  • Function : Author
  • PersonId : 919930
Shibo Jiang
  • Function : Author
  • PersonId : 919931
Bo-Jian Zheng
  • Function : Author
  • PersonId : 919933

Abstract

BACKGROUND: A 2009 global influenza pandemic caused by a novel swine-origin H1N1 influenza A virus has posted an increasing threat of a potential pandemic by the highly pathogenic avian influenza (HPAI) H5N1 virus, driving us to develop an influenza vaccine which confers cross-protection against both H5N1 and H1N1 viruses. Previously, we have shown that a tetra-branched multiple antigenic peptide (MAP) vaccine based on the extracellular domain of M2 protein (M2e) from H5N1 virus (H5N1-M2e-MAP) induced strong immune responses and cross-protection against different clades of HPAI H5N1 viruses. In this report, we investigated whether such M2e-MAP presenting the H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic 2009 H1N1 virus. RESULTS: Our results demonstrated that H5N1-M2e-MAP plus Freund's or aluminum adjuvant induced strong cross-reactive IgG antibody responses against M2e of the pandemic H1N1 virus which contains one amino acid variation with M2e of H5N1 at position 13. These cross-reactive antibodies may maintain for 6 months and bounced back quickly to the previous high level after the 2nd boost administered 2 weeks before virus challenge. H5N1-M2e-MAP could afford heterosubtypic protection against lethal challenge with pandemic H1N1 virus, showing significant decrease of viral replications and obvious alleviation of histopathological damages in the challenged mouse lungs. 100% and 80% of the H5N1-M2e-MAP-vaccinated mice with Freund's and aluminum adjuvant, respectively, survived the lethal challenge with pandemic H1N1 virus. CONCLUSIONS: Our results suggest that H5N1-M2e-MAP has a great potential to prevent the threat from re-emergence of pandemic H1N1 influenza and possible novel influenza pandemic due to the reassortment of HPAI H5N1 virus with the 2009 swine-origin H1N1 influenza virus.
Fichier principal
Vignette du fichier
1743-422X-7-151.pdf (855.15 Ko) Télécharger le fichier
1743-422X-7-151.xml (39.85 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive
Format Other
Loading...

Dates and versions

inserm-00668214 , version 1 (09-02-2012)

Identifiers

Cite

Guangyu Zhao, Shihui Sun, Lanying Du, Wenjun Xiao, Zhitao Ru, et al.. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.. Virology Journal, 2010, 7 (1), pp.151. ⟨10.1186/1743-422X-7-151⟩. ⟨inserm-00668214⟩
149 View
1006 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More